Frontage Expands Clinical Operations in Secaucus, NJ
News May 07, 2015
Frontage has announced the opening of its newest facility in Secaucus, NJ to expand its clinical research portfolio of services.
As part of Frontage’s strategic growth plans to broaden clinical service capabilities and increase capacity, the company has completed construction of its new 36,000-square-foot 160-bed clinical research center in Secaucus, NJ.
The location of the new facility complements the existing center in nearby Hackensack. The Secaucus facility will include the ability to conduct a wider range of clinical studies including multiple concurrent studies and Phase II-IV studies involving patient populations. This expansion will nearly triple the company’s clinical capacity in the USA.
“We are excited to operate a second facility in New Jersey as it has been an ideal location for our clinical research due to the immediate access to the medical communities as well as subject and patient populations,” said Eileen McAuley, Senior Vice President of Clinical Services.
“Frontage’s ability to provide comprehensive support to our clients and their needs in the early drug development stage is greatly enhanced by our investment in facility expansion and clinical services infrastructure,” said Dr. Song Li, CEO of Frontage.
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE